Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
Craig Lammert, Einar Bjornsson, Anna Niklasson, Naga Chalasani – 25 January 2010 – Reactive metabolites generated by hepatic metabolism are thought to play an important role in the pathogenesis of drug‐induced liver injury (DILI), but supporting data are limited. If this is true, then compounds with significant hepatic metabolism should cause more DILI than those without it. We conducted a study to examine the relationship between hepatic metabolism and DILI of prescription medications.